DIVIS LABORATORIES

BSE: 532488 30 Sep 2025

Healthcare

₹ 6041.05

Divi's Laboratories Ltd. specializes in Pharmaceuticals within the Healthcare sector.

DIVIS LABORATORIES

BSE: 532488 30 Sep 2025

Healthcare

₹ 6041.05

Divi's Laboratories Ltd. specializes in Pharmaceuticals within the Healthcare sector.

Book Value

564.0

Dividend Yield

0.53%

Debt to Equity

0.0

Stock P/E

65.5

Market Cap

1,51,038 Cr

DIVIS LABORATORIES - Share Price & Details

Market Cap

₹1,51,038

High /Low

7,078 / 4,942

Stock P/E

65.5

Book Value

₹564.0

Dividend Yield

0.53

ROCE

20.4

ROE

₹15.4

Face Value

2.0

PEG Ratio

-6.84

EVEBITDA

₹42.5

Debt

4.00

CMP / FCF

184.0

Debt to equity

₹0.0

NP Ann

2,191

High price all time

7,078

Piotroski score

₹7.0

Graham Number

1,050

No. Eq. Shares

26.6

Net CF

₹50.0

Net profit

2,306

Price to book value

10.1

Interest Coverage

₹610.0

Low price all time

45.0

Industry PE

33.0

Reserves

₹14,916

Free Cash Flow

₹215

Broker Recommendations

Date	Author	Type	Reco Price	Target Price	Potential	Source	PDF Link
10 Sep 2025	Geojit Financial Services	Sell	₹6,000.05	₹5,400	-10.4%	moneycontrol	View
07 Aug 2025	Prabhudas Lilladher	Buy	₹6,134.25	₹6,550	6.8%	moneycontrol	View
23 May 2025	ICICI Securities	Sell	₹6,451.2	₹5,610	-14.3%	moneycontrol	View
23 May 2025	Deven Choksey	Buy	₹6,538.3	₹7,518	15.9%	moneycontrol	View
19 May 2025	ICICI Securities	Sell	₹6,583.65	₹5,610	-13.4%	moneycontrol	View
05 Feb 2025	KRChoksey	Buy	₹6,092.2	₹6,435	5%	moneycontrol	View
04 Feb 2025	Prabhudas Lilladher	Buy	₹5,889.3	₹6,250	2.5%	moneycontrol	View
03 Feb 2025	Motilal Oswal	Hold	₹5,889.3	₹6,200	1.2%	moneycontrol	View
11 Nov 2024	Sharekhan	Buy	₹5,893.8	₹6,812	9%	moneycontrol	View
11 Nov 2024	Prabhudas Lilladher	Buy	₹5,893.8	₹6,000	-3.9%	moneycontrol	View
06 Nov 2024	Prabhudas Lilladher	Sell	₹5,939.7	₹1,335	-78.6%	moneycontrol	View
04 Aug 2024	ICICI Securities	Sell	₹4,990.35	₹3,670	-41.2%	moneycontrol	View
04 Aug 2024	Prabhudas Lilladher	Buy	₹4,990.35	₹5,000	-19.4%	moneycontrol	View
29 Jul 2024	Prabhudas Lilladher	Sell	₹4,923.25	₹6,000	-3.3%	moneycontrol	View
28 May 2024	KRChoksey	Hold	₹4,390.85	₹4,478	-27.8%	moneycontrol	View
27 May 2024	Prabhudas Lilladher	Buy	₹4,254	₹4,350	-29.9%	moneycontrol	View
03 Apr 2024	KRChoksey	Buy	₹3,684	₹3,931	-36.7%	moneycontrol	View

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.09	84.8
Triochem Products Ltd.,	NA	NA	NA	NA	0
DIVIS LABORATORIES LTD.	24760.0	5570.0	23570.0	20.95	1,51,038	65.5
CIPLA LTD.	53172.4	13031.3	50461.7	16.12	121115	22.5
TORRENT PHARMACEUTICALS LTD.	26110.0	5510.0	26160.0	16.28	120515	59.7

Peer Comparison Chart

About DIVIS LABORATORIES

Divi's Laboratories Ltd., with Security Code 532488, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Order Book

Latest News

Divis Labs Share Price Live Updates: Divis Labs struggles with recent performance

(15 Sep 2025)

Stay up-to-date with the Divis Labs Stock Liveblog, your trusted source for real-time updates and thorough analysis of a prominent stock.

Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain

(14 Sep 2025)

Navigating the complexities of the pharmaceutical industry, from innovator economics to generics, CRDMO, and biosimilars for growth...

Quarterly Table

Standalone Consolidated

Metrics	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	1,908.2	1,730.0	1,868.0	1,808.0	2,259.0	2,063.0	2,302.0	2,297.0	2,536.0	2,357.0
Expenses	1,419.5	1,239.0	1,394.0	1,317.0	1,542.0	1,442.0	1,573.0	1,550.0	1,655.0	1,614.0
Operating Profit	488.7	491.0	474.0	491.0	717.0	621.0	729.0	747.0	881.0	743.0
OPM %	25.61%	28.38%	25.37%	27.16%	31.74%	30.1%	31.67%	32.52%	34.74%	31.52%
Other Income	66.2	80.0	85.0	94.0	79.0	79.0	105.0	82.0	87.0	119.0
Interest	0.2	0.0	1.0	0.0	2.0	0.0	1.0	0.0	0.0	3.0
Depreciation	86.6	93.0	94.0	95.0	94.0	97.0	98.0	99.0	107.0	112.0
Profit before tax	468.0	478.0	464.0	490.0	700.0	603.0	735.0	730.0	861.0	747.0
Tax %	-31.9%	-27.8%	-26.3%	-26.9%	-24.1%	28.7%	-29.5%	-18.6%	-22.5%	25.4%
Net Profit	318.8	345.0	342.0	358.0	531.0	430.0	518.0	594.0	667.0	557.0
EPS in Rs	12.01	12.99	12.89	13.5	19.99	16.18	19.51	22.39	0	20.95

Metrics	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	1,707.7	1,950.8	1,778.0	1,909.0	1,855.0	2,303.0	2,118.0	2,338.0	2,319.0	2,585.0
Expenses	1,299.4	1,463.2	1,274.0	1,430.0	1,366.0	1,572.0	1,496.0	1,622.0	1,576.0	1,699.0
Operating Profit	408.3	487.6	504.0	479.0	489.0	731.0	622.0	716.0	743.0	886.0
OPM %	23.91%	24.99%	28.35%	25.09%	26.36%	31.74%	29.37%	30.62%	32.04%	34.27%
Other Income	114.3	66.2	81.0	86.0	95.0	79.0	79.0	106.0	82.0	86.0
Interest	0.1	0.2	0.0	1.0	0.0	2.0	0.0	1.0	0.0	1.0
Depreciation	86.8	87.0	93.0	95.0	95.0	95.0	97.0	99.0	99.0	107.0
Profit before tax	435.6	466.5	492.0	469.0	489.0	713.0	604.0	722.0	726.0	864.0
Tax %	-29.6%	-31.2%	-27.6%	-25.8%	-26.8%	-24.5%	-28.8%	29.4%	18.9%	-23.4%
Net Profit	306.8	321.0	356.0	348.0	358.0	538.0	430.0	510.0	589.0	662.0
EPS in Rs	11.56	12.09	13.41	13.11	13.5	20.25	16.2	19.2	22.2	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	12%
5 Years:	12%
3 Years:	1%
TTM:	20%

Compounded Profit Growth
10 Years:	10%
5 Years:	11%
3 Years:	-9%
TTM:	40%

Stock Price CAGR
10 Years:	22%
5 Years:	23%
3 Years:	21%
1 Year:	59%

Compounded Sales Growth
10 Years:	12%
5 Years:	12%
3 Years:	1%
TTM:	19%

Compounded Profit Growth
10 Years:	10%
5 Years:	10%
3 Years:	-10%
TTM:	37%

Stock Price CAGR
10 Years:	22%
5 Years:	23%
3 Years:	21%
1 Year:	59%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Stock Mutual Funds Data

Order Book

News Date ▲▼	Headline ▲▼	Issuer Entity ▲▼	Issuer Type ▲▼	Order Size ▲▼	Time Period ▲▼
Loading company updates…

Loading technicals…

Moving Averages

Latest Close: — • Records Used: — • Last Trading Date: —

Simple Moving Averages (SMA)

Period	SMA Value	Status

Exponential Moving Averages (EMA)

Period	EMA Value	Status

Oscillators

Key Oscillators

latest calculation

Indicator	Value

DIVIS LABORATORIES

DIVIS LABORATORIES

DIVIS LABORATORIES - Share Price & Details

Broker Recommendations

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About DIVIS LABORATORIES

Order Book

Latest News

DIVISLAB Outlook for the Week

Divi’s Laboratories stock initiated at Overweight by JPMorgan on GLP-1 growth

Stocks To Buy: JPMorgan bets on two CRDMO plays; Check price targets

Indian Pharma Exports Surge In August: Laurus, Divis Lead Growth

Divis Labs Share Price Live Updates: Divis Labs struggles with recent performance

Sun Pharma, Cipla, Dr Reddy’s, Zydus Lifesciences, Divi’s Labs, Torrent Pharma et al: Parsing through the pharma value chain

Reduce Divis Laboratories; target of Rs 5400: Geojit Financial Services

Divi's Labs: Geojit downgrades stock to 'Reduce' with Rs 5,400 target

Divi’s Laboratories Q1 Results: Cons net profit rises 27% YoY to Rs 545 crore, revenue up 14%

Nuvama sees 15% upside in this pharma stock: 3 reasons revealed

Divi's Labs share: Nuvama says 'Buy', sees growing GLP-1 opportunities

Divis Labs Shares In Focus As Jefferies Upgrades To Buy, Eyes 16% Upside On Sustained Growth Momentum

Divi's Laboratories Limited Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Divi's Lab, Mankind Pharma among 7 largecap stocks below their 200 DMAs

Divis Laboratories posts consolidated Q1 FY26 PAT of Rs. 545 Cr

Divis Laboratories Faces Continued Stock Decline Amid Broader Market Challenges

DIVISLAB Outlook for the Week (August 11, 2025 – August 15, 2025)

Divi's Labs falls 4% after Q1 miss, analysts trim estimates; check details

Divi's Laboratories Q1 Results: Stock falls after profit, margins miss estimates

Divi's Laboratories' June-quarter profit, margin miss estimates

Divi’s Lab donates ₹3.21 crore to boost AU’s infrastructure

Divis Labs bucks weak pharma shares trend; hits new high on strong Q1 hopes

Divi's Laboratories shares fall 4% after IIFL warns of material risk to earnings

Divi's Laboratories shares get an upgrade from HSBC who raises price target by 57%

Divis Laboratories Sees Significant Open Interest Surge Amid Active Market Participation

Divis Laboratories Sees Significant Open Interest Surge Amid Increased Trading Activity

DIVISLAB Outlook for the Week (June 30, 2025 – July 04, 2025)

DIVISLAB Outlook for the Week (June 09, 2025 – June 13, 2025)

Divi’s Lab shares up 3% after Q4 PAT surges 26% YoY. Should you invest?

Divis Labs Share Price Live Updates: Divis Labs Trading Insights

Divi's Laboratories inks manufacturing and supply agreement with global pharma company

Divi's Labs share up 4%, hits record high on inking supply deal; details

Divis Lab inks long-term global pharma deal

DIVIS LAB ENTERS INTO A LT MANUFACTURING AND SUPPLY AGREEMENT WITH A GLOBAL PHARMA CO

Divi's Laboratories share price rises 6% post Q4 results, dividend announcement: Time to buy or sell?

Stocks to buy in 2025: BHEL, Divi’s Laboratories among 5 stocks that could give 10-40% return

Stocks to buy for short term: From Divi's Labs, IRFC to Concor— experts suggest THESE 5 stock picks

Divi’s Labs Shares Jump Over 5%, Hits 52-Week High: Here's Why

From Vodafone Idea, BEL, Divi’s Lab to Premier Energies- Here are 8 stocks to watch

Divi’s Laboratories shares rally 6% on strong Q4 show; should you buy, sell or hold?

Divis and Delhivery gain up to 11%; Heres how market guru Anil Singhvi views companies earnings

Strong growth seen for Divi's Laboratories, but upside capped by valuations

Analyst predicts fresh upside for Divi’s Labs if ₹6,410 breaks | Tap to know more | Inshorts

Divi’s Labs Surges 6% On Q4 Beat; SEBI RA Thoviti Brahmachary Predicts Fresh Upside If ₹6,410 Breaks By Stocktwits

Divi's Labs shares gain 4% on strong Q4 show; eyes double-digit growth for FY26

Divis Laboratories Achieves 52-Week High, Signaling Strong Market Performance and Operational Efficiency

Divi’s Labs Q4 Results: Profit up 23% YoY, beats estimates; declares ₹30 dividend

Q4 Results Live: Data Patterns Profit Up, Margin Contracts; Zen Technologies Profit Jumps

Divi’s Laboratories Q4 results: PAT surges 26% YoY, revenue up 12%

Divis Labs Share Price Live Updates: Divis Labs Weekly Performance Highlights

Divis Laboratories Faces Short-Term Decline Amid Broader Market Volatility

Divi’s Labs inks long-term pact with global pharma firm to make, supply advanced intermediates

Stock Picks: Sagar Doshi suggests Divis Lab, HCL Tech, Marico shares to buy amid Indo-Pak conflict

Divi's Laboratories Insiders Sold ₹620m Of Shares Suggesting Hesitancy

Citi raises its price target on its top pharma pick, sees a 19% upside on the stock

Divis Labs jumps on signing long-term manufacturing pact with global pharma major

Stock to buy today: Divi’s Laboratories (₹6,215.55) – BUY

Divi's Laboratories Shows Strong Financial Growth and Market Positioning Amid Evaluation Adjustment

Divi’s Laboratories Shares Rally 5% Iking Deal with Global Pharma Company

Divi's Labs jumps 4% after signing supply agreement with global pharma firm

Divis Laboratories enters into long term manufacturing and supply agreement

Divis Laboratories Inks Supply Pact With Global Pharmaceutical Entity

Divi's Labs Q3 Results: Stock surges on earnings beat, part of a key unit begins commercial operations

Divi’s Laboratories Q3 Results: Profit Rises 64%, Beats Estimates

Sell Divi's Laboratories, target price Rs 4,500: ICICI Securities

Divis Labs shares surge 5% on Q3 beat; target prices, outlook & more

Divi’s Laboratories Q3 Results: Net profit rises 64.5% YoY to ₹589 crore, stock surges nearly 4%

Divi's Labs: Strong Q3, growth outlook positive, valuation debate continues

Divis Labs shares 0.3% as Nifty gains